Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 2/20 | 0.47 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075581 | 0.91 | MEN1 (0.48) | IDO1TDO2IDO2FAAHCYP2D6 | |
| SCHEMBL4186957 | 0.85 | FAAH (0.39) | IDO1TDO2IDO2OPRM1OPRL1 | |
| SCHEMBL11402799 | 0.82 | DRD3 (0.53) | OPRM1OPRD1OPRK1CYP2D6DRD3 | |
| SCHEMBL4077695 | 0.81 | MEN1 (0.58) | CYP2D6DRD3MEN1TP53CYP1A2 | |
| SCHEMBL4079337 | 0.80 | IDO1 (0.51) | IDO1TDO2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4189078 | 0.78 | MEN1 (0.49) | FAAHCYP2D6DRD3MEN1TP53 | |
| SCHEMBL9450757 | 0.76 | SLC6A4 (0.45) | DRD3CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL4075659 | 0.75 | OPRM1 (0.45) | IDO1TDO2OPRM1OPRL1OPRD1 | |
| SCHEMBL4182438 | 0.75 | FAAH (0.62) | FAAHKCNH2 | |
| SCHEMBL4084971 | 0.75 | CNR1 (0.44) | OPRM1OPRL1OPRD1OPRK1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | disclosed |
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | CNR1, CNR2, GPR119 | IDO1 1142/4885TDO2 1669/4885IDO2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.